Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310544 · ClinicalTrials.gov registry record · Phase 2
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00310544: Completed Phase 2 study, sponsored by Bayer.
NCT00310544 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 73 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310544, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.
Interventions
- DRUG Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00310544 record still lists
NCT00310544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 1 intervention - of which Magnevist (Gadopentetate dimeglumine, BAY86-4882) is the first listed.
NCT00310544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00310544 about?
NCT00310544 is a clinical study titled "Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction". The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.
What is the current status of trial NCT00310544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2006-03. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00310544?
The interventions under investigation include: Magnevist (Gadopentetate dimeglumine, BAY86-4882) (DRUG).
Who is sponsoring clinical trial NCT00310544?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00310544's enrollment target sits among peer trials
73 924th of 2000 higher than 1,076 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia